Skip to main content

Table 4 Clinical outcomes in the nineteen patients treated with tomotherapy and concurrent capecitabine

From: Helical tomotherapy with concurrent capecitabine for the treatment of inoperable pancreatic cancer

Patient Overall In-field tumor response Duration of tumor response (months) Treatment-related toxicity Duration of follow-up after tomotherapy (months) Out-field progression state Cause of death other than cancer progression Duration of survival after tomotherapy (months)
1 Stable disease 5.9 fatigue (grade 2) 7.3 Progressed   7.3
2 Partial response   hand foot syndrome (grade 1) 3.2    4.8
3 Stable disease    10.7    11.2
4 Stable disease 3.8   5.8 Progressed   5.8
5     1.1   Pneumonia 1.1
6 Partial response   fatigue (grade 2) 6.8    13.9
7 Stable disease 6.9   15 Progressed   16.3
8     1.8    1.9
9 Partial response 2.4 nausea (grade 1) 4.4 Progressed   4.4
10 Partial response    13.6    13.9
11 Stable disease 4.1 fatigue (grade 1) 4.1 Stable disease Pulmonary thromboembolism 4.1
12 Stable disease 2.2   3.4 Progressed   3.9
13 Stable disease 2.5   6.5 Progressed   6.5
14     2   DUB, Pneumonia 2
15 Stable disease    10.5    10.5
16 Partial response 7.3   7.3 Stable disease Pneumonia 7.3
17 Partial response    14.9    18.4
18 Partial response    17.6    21
19 Partial response 3.2   6.2 Progressed   6.5
  1. DUB, duodenal malignant ulcer bleeding